Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Onventis in connection with their acquisition of Spendency AB
Mandate

Vinge advises Main Capital and Onventis in connection with their acquisition of Spendency AB

November 29, 2021 Employment and Benefits Commercial Agreements Intellectual Property IT, Telecommunications and Outsourcing M&A

Established in 2015, with headquarters in Stockholm, Spendency has grown into a leading spend analytics provider.

Connected directly to the clients’ ERP and/or procurement system, Spendency helps its customers to collect, enrich and normalise supplier data. Spendency serves a vast customer base of more than 100 customers and over 1,500 users. Through the acquisition, Onventis strategically expands its product offering within spend analytics.

Vinge’s team consisted of Filip Öhrner and Eléonore Friberg (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (Agreements), Karolina Fuhrman (GDPR/IT), Arvid Axelryd (IP) and Jessica Henning (VDR).

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026